Advertisement

Topics

New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod

20:15 EDT 1 Aug 2017 | News-Medical.net

The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.

Original Article: New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod

NEXT ARTICLE

More From BioPortfolio on "New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...